Citius Pharmaceuticals, Inc. (CTXR)

0,7165 -0,0508 (-6,62%) Alla chiusura: 04:00PM EDT

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677
https://citiuspharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 22

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Leonard L. Mazur	Co-Founder, CEO, Chairman & Secretary	676,88k	N/D	1945
Mr. Myron Z. Holubiak	Co-Founder & Executive Vice Chairman	641,25k	N/D	1947
Dr. Myron S. Czuczman M.D.	Executive VP & Chief Medical Officer	571,38k	N/D	1960
Mr. Jaime Bartushak	Chief Business Officer, CFO & Chief Accounting Officer	527,97k	N/D	1968
Mr. Gary F. Talarico	Executive Vice President of Operations	N/D	N/D	1955
Ms. Ilanit Allen	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Dr. Alan Lader Ph.D.	Senior VP and Head of Clinical Operations & Quality Assurance	N/D	N/D	N/D
Mr. Dhananjay G. Wadekar	Senior Vice President of Business Strategy	N/D	N/D	1954
Mr. Kelly Creighton Ph.D.	Executive Vice President of Chemistry, Manufacturing & Controls	N/D	N/D	N/D
Mr. Nikolas Burlew	Executive Vice President of Quality Assurance	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Citius Pharmaceuticals, Inc. al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.